The major aim of the DF&DDS Research Group is formulation of the conventional and modified-release dosage forms (DF). Special attention is paid to development and testing of micro- and nanoparticle carrier drug delivery systems (DDS), mainly for antineoplastic and nonsteroidal anti-inflammatory drugs. The group also deals with improvement solubility/bioavailability of BCS II/IV drugs using specific technological procedures such as liquisolid systems, self-emulsifying systems or co/milling with specific carriers.
|
Improvement in API solubility & release
|
 |
|
3D printing
|
 |
|
Mesoporous silica-based systems
|
 |
|
PLGA drug delivery systems
|
 |